在平均风险女性乳腺筛查中,数字乳腺X线摄影与数字乳腺断层合成基础上加做筛查乳腺超声
回顾性纳入2016年3月至2018年12月同时接受数字乳腺X线摄影/数字乳腺断层合成(DM/DBT)与放射科医师操作的筛查乳腺超声的1003例无症状平均风险女性,比较两种方案的癌症检出率、敏感度、特异度与异常判读率。DM/DBT加超声使每1000次筛查的癌症检出率由9.0增至12,异常判读率由7.8%升至24%;在DM/DBT阴性者中补充超声检出3例癌症,均见于致密乳腺,非致密乳腺未见获益。
要点
- DM/DBT加超声的癌症检出率为每1000次筛查12例(95%CI 6.2, 21),DM/DBT单独为每1000次筛查9.0例(95%CI 4.1, 17)。
- 加做超声使异常判读率由7.8%(95%CI 6.2, 9.6)升至24%(95%CI 22, 27)。
- DM/DBT阴性者补充超声检出3例癌症,均在致密乳腺女性,非致密乳腺女性未见获益。
核心结论
- 在平均风险女性中,DM/DBT加做乳腺超声每1000例可额外检出0.7-9.4例癌症,同时异常判读率大幅升高。
- 补充超声检出的3例额外癌症均见于致密乳腺女性,非致密乳腺女性未见获益。
研究设计与样本
- 回顾性数据库检索,连续纳入2016年3月至2018年12月同时接受DM/DBT与放射科医师操作的筛查乳腺超声的无症状女性。
- 共纳入1003例女性,平均年龄56岁±8.6(标准差)。
- 比较DM/DBT与DM/DBT联合超声的每1000次筛查癌症检出率、敏感度、特异度及异常判读率。
关键影像表现/征象
- 共诊断12例癌症,浸润性肿瘤平均大小14 mm(范围6-33 mm)。
- DM/DBT阴性(925例)者补充超声检出3例癌症,该3例均见于致密乳腺女性。
- 非致密乳腺女性中未观察到补充超声的获益。
诊断标准与关键数值
- DM/DBT的癌症检出率为每1000次筛查9.0例(1003例中9例;95%CI 4.1, 17),异常判读率为7.8%(1003例中78例;95%CI 6.2, 9.6)。
- DM/DBT联合超声的癌症检出率为每1000次筛查12例(1003例中12例;95%CI 6.2, 21),异常判读率为24%(1003例中243例;95%CI 22, 27)。
- DM/DBT阴性者补充超声的癌症检出率为每1000次检查3.2例(925例中3例;95%CI 0.7, 9.4)。
- DM/DBT阴性者补充超声的敏感度为100%(3例中3例;95%CI 29, 100),特异度为82%(922例中760例;95%CI 80, 85),异常判读率为18%(925例中165例;95%CI 15, 21)。
临床应用与阅片要点
- 原文结论指出,在平均风险女性中DM/DBT加做乳腺超声可额外检出0.7-9.4例/1000例癌症,但异常判读率大幅升高。
- 原文报告补充超声检出的额外癌症均见于致密乳腺女性,非致密乳腺女性未见获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Digital breast tomosynthesis (DBT) with or without digital mammography (DM) is the primary method of breast cancer screening. However, the sufficiency of DBT screening for women at average risk and the need for supplemental whole-breast US needs further investigation. Purpose To evaluate the added value of supplemental US screening following combined DM/DBT. Materials and Methods A retrospective database search identified consecutive asymptomatic women who underwent DM/DBT and radiologist-performed screening breast US simultaneously between March 2016 and December 2018. The cancer detection rate (CDR) per 1000 screening examinations, sensitivity, specificity, and abnormal interpretation rate of DM/DBT and DM/DBT combined with US were compared. Results A total of 1003 women (mean age, 56 years ± 8.6 [standard deviation]) were included. Among them, 12 cancers (mean invasive tumor size, 14 mm; range, 6-33 mm) were diagnosed. With DM/DBT and DM/DBT combined with US, the CDRs were 9.0 per 1000 screening examinations (nine of 1003 women; 95% CI: 4.1, 17) and 12 per 1000 screening examinations (12 of 1003 women; 95% CI: 6.2, 21), respectively, and the abnormal interpretation rates were 7.8% (78 of 1003 women; 95% CI: 6.2, 9.6) and 24% (243 of 1003 women; 95% CI: 22, 27). In women with negative findings at DM/DBT, supplementary US yielded a CDR of 3.2 per 1000 examinations (three of 925 women; 95% CI: 0.7, 9.4), sensitivity of 100% (three of three women; 95% CI: 29, 100), specificity of 82% (760 of 922 women; 95% CI: 80, 85), and abnormal interpretation rate of 18% (165 of 925 women; 95% CI: 15, 21). The three additional US-detected cancers were identified in women with dense breasts; no benefit was observed in women with nondense breasts. Conclusion The addition of breast US to digital mammography and digital breast tomosynthesis yielded an additional 0.7-9.4 cancers per 1000 women at average risk, with a substantial increase in the abnormal interpretation rate. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Rahbar in this issue.
引用
- Yi A, Jang MJ, Yim D, et al. Addition of Screening Breast US to Digital Mammography and Digital Breast Tomosynthesis for Breast Cancer Screening in Women at Average Risk. Radiology. 2021. PMID: 33434108. doi:10.1148/radiol.2021203134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。